EFFECTIVENESS OF NOVEL PHARMACOTHERAPY STRATEGIES IN PATIENTS WITH CHRONIC HEART FAILURE
Keywords:
chronic heart failure, pharmacotherapy, SGLT2 inhibitors, ARNIs, combination therapy, clinical outcomes.Abstract
Chronic heart failure (CHF) remains a leading cause of morbidity and mortality worldwide, necessitating the development of effective pharmacotherapy strategies. Recent studies have highlighted the potential of novel pharmacological approaches, including SGLT2 inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and combination therapies, in improving cardiac function, reducing hospitalizations, and enhancing patients’ quality of life [1,2]. These strategies demonstrate significant benefits in symptom control, ejection fraction improvement, and long-term survival compared to conventional treatment. Challenges such as patient adherence, comorbidities, and individualized responses require careful monitoring and tailored therapeutic plans. Overall, integrating these modern pharmacotherapy strategies into routine CHF management offers promising outcomes and may redefine standard care protocols [3,4].
Downloads
References
Huang Y, Fang C, Zhang YY, Ma L, Zhou H, Ye H. Effectiveness and safety of angiotensin receptorneprilysin inhibitor and sodiumglucose cotransporter2 inhibitors for patients with heart failure with reduced ejection fraction: a metaanalysis. J Cardiovasc Med (Hagerstown). 2023;24(2):123131.
Ezhumalai B, Modi R, Panchanatham M, Kaliyamoorthy D. The contemporary role of sodiumglucose cotransporter 2 inhibitor (SGLT2i) and angiotensin receptorneprilysin inhibitor (ARNI) in the management of heart failure: Stateoftheart review. Int Heart J. 2024;76(4):229239.
Tang H, Germinal K, Milfort A, et al. The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network metaanalysis of randomized controlled trials. BMC Cardiovasc Disord. 2024;24:666.
Tang J, Wang P, Liu C, et al. Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and metaanalysis. Chin Med J (Engl). 2025;138(8):925933.
Ji PJ, Zhang ZY, Yan Q, et al. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. ESC Heart Fail. 2023;10(2):13141325.
Nedogoda SV, Zhuravleva MV, Tereshchenko SN, et al. Clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure with reduced left ventricular ejection fraction. Ter Arkhiv. 2024;96(8):771779.
Uskach TM. Empagliflozin as a part of optimal medical therapy for chronic heart failure. Cardiological Bulletin. 2022;17(2):1624.
Wikipedia contributors. Empagliflozin. Wikipedia, The Free Encyclopedia. 2026.
Singh P, Sunkara A, Muskan F, et al. Comparative Effectiveness of SGLT2 inhibitors versus ARNIs in heart failure with reduced ejection fraction: A systematic review. Cureus. 2025;17(4):e83166.
European Society of Cardiology. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021. (Guideline document).
Fontana N, Savaré L, Rea F, et al. Longterm adherence to polytherapy in heart failure patients: a novel approach emphasising the importance of secondary prevention. arXiv. 2023.
Zhirov IV, Safronova NV, Tereshchenko SN. Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review. Ter Arkhiv. 2023;95(9):802809.
Safronova NV, Zhirov IV, Tereshchenko SN. Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. Consilium Medicum. 2022;24(1):2835.
American Heart Association; Heart Failure Society of America. Guideline for the management of heart failure. Circulation. (Guideline resource).
Contemporary RealWorld Use of SGLT2i and ARNi in Patients with Atrial Fibrillation and Heart Failure (2024). PubMed.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.
